At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,613 enrolled
Drug / intervention
Simponi® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
In Brief
An observational study evaluating Simponi® and Methotrexate for Arthritis, Rheumatoid and 2 related conditions. Completed, enrolled 1,613 participants.
Detailed Summary
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMar 2011
Primary CompletionSep 2015
TodayJul 2026
First PostedMar 14, 2011
Enrollment StartApr 1, 2010
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 15.3 years ago
Interventions
Simponi®drug
Methotrexatedrug
Given concomitantly with Simponi®